title: Antinuclear antibodies testing as a routine screening for systemic lupus erythematosus in patients presenting first-episode psychosis.
abstract: OBJECTIVE
  This report discusses the use of antinuclear antibody (ANA) detection as a screening test for neuropsychiatry systemic lupus erythematosus (NPSLE) in patients presenting a first-episode psychosis.
  
  
  METHODS
  We reviewed the medical records of 85 patients admitted to an emergency service due to first-episode psychosis, during a 1-year period, for whom ANA detection was performed through an IFI HEp2 cell assay. ANA-positive patients were subsequently evaluated for autoantibodies and neuroimaging exams.
  
  
  RESULTS
  Three patients presented as ANA positive in the initial screening and further investigation confirmed NPSLE in two patients. The patients were treated with antipsychotics and cyclophosphamide pulses with satisfactory outcomes.
  
  
  CONCLUSIONS
  Even though ANA detection is not specific, it is a low-cost procedure and could be an important screening test for NPSLE in the early-onset psychosis.
authors.affiliation: Department of Neurosciences and Behaviour, Division of Psychiatry, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
authors.forename: Célia
authors.initials: C
authors.lastname: Mantovani
authors.forename: Paulo
authors.initials: P
authors.lastname: Louzada-Junior
authors.forename: Emerson Arcoverde
authors.initials: EA
authors.lastname: Nunes
authors.forename: Felipe Pinheiro
authors.initials: FP
authors.lastname: de Figueiredo
authors.forename: Glício Rebouças
authors.initials: GR
authors.lastname: Oliveira
authors.forename: Cristina Marta
authors.initials: CM
authors.lastname: Del-Ben
mesh_terms: D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003955:Diagnostic Tests, Routine / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D020945:Lupus Vasculitis, Central Nervous System / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012189:Retrospective Studies
chemical_list: D000974:Antibodies, Antinuclear; D014150:Antipsychotic Agents; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide